Johan Lundberg's research group

Molecular imaging, neuropsychopharmacology, mood and anxiety disorders

Johan LundbergThe overriding aim of our research is to improve the treatment of major psychiatric disorders. Our main activity involves in vivo and post mortem molecular imaging to study the pathophysiology and pharmacology of mood and anxiety disorders, and to some extent autism spectrum disorders.

One vision of the group is to develop imaging markers for antidepressant treatment response. To this end, we study the molecular effect in man in vivo of different antidepressant treatments, such as Cognitive Behavioral Treatment, antidepressant drug treatment, Electro Convulsive Treatment and novel antidepressant treatments such as ketamine. We have had a focus on the serotonin system, but are performing studies also on the GABA and Glutamate systems. The development of molecular imaging analysis and statistics is an integrated part of our work.

Our work is supported by the Swedish Science Council, the Stockholm County, the Söderström-Königska foundation and from a generous private donation.

Group members

Max AnderssonGraduate Student
Carl Johan EkmanAssociated, Postdoc
Johan LundbergAssociated, Research team leader
Jonas SvenssonGraduate Student
Mikael TigerAssociated, Postdoc
Emma VeldmanPhD student, Graduate Student

Media appearances


Selected publications

Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2.
Arakawa R, Stenkrona P, Takano A, Svensson J, Andersson M, Nag S, et al
Int. J. Neuropsychopharmacol. 2019 Apr;22(4):278-285

GABA receptor availability is not altered in adults with autism spectrum disorder or in mouse models.
Horder J, Andersson M, Mendez M, Singh N, Tangen , Lundberg J, et al
Sci Transl Med 2018 Oct;10(461):

The 5-HT receptor - a potential target for antidepressant treatment.
Tiger M, Varnäs K, Okubo Y, Lundberg J
Psychopharmacology (Berl.) 2018 05;235(5):1317-1334

Associations between cognition and serotonin receptor 1B binding in patients with major depressive disorder - A pilot study.
Tangen , Borg J, Tiger M, Varnäs K, Sorjonen K, Lindefors N, et al
Psychiatry Res Neuroimaging 2017 Sep;267():15-21

Distribution and levels of 5-HT receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia - An autoradiography study.
Veldman E, Svedberg M, Svenningsson P, Lundberg J
Eur Neuropsychopharmacol 2017 05;27(5):504-514

Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder.
Tiger M, Farde L, Rück C, Varrone A, Forsberg A, Lindefors N, et al
Psychiatry Res Neuroimaging 2016 07;253():36-42

No correlation between serotonin and its metabolite 5-HIAA in the cerebrospinal fluid and [(11) C]AZ10419369 binding measured with PET in healthy volunteers.
Tiger M, Svenningsson P, Nord M, Jabre S, Halldin C, Lundberg J
Synapse 2014 Oct;68(10):480-3

Reduced 5-HT(1B) receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder.
Tiger M, Rück C, Forsberg A, Varrone A, Lindefors N, Halldin C, et al
Psychiatry Res 2014 Aug;223(2):164-70

5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
Stenkrona P, Halldin C, Lundberg J
Eur Neuropsychopharmacol 2013 Oct;23(10):1190-8

Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.
Lundberg J, Tiger M, Landén M, Halldin C, Farde L
Int. J. Neuropsychopharmacol. 2012 Sep;15(8):1167-72

A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain.
Lundberg J, Borg J, Halldin C, Farde L
Psychopharmacology (Berl.) 2007 Dec;195(3):425-33